HMGBiotech has taken part to a recent study in which have been discovered CXCL12 as the first fuzzy chemokines heterocomplex reported so far and the unexpected role of the acidic intrinsically disordered region (IDR), in HMGB1●CXCL12 heterocomplex formation.
The research highlights how intervering on the interactions in the HMGB1●CXCL12 complex could potentially inhibit its harmful effects in inflammatory conditions.
From an integrative structural approach using NMR, AUC, ITC, MST, and SAXS, this findings open the way to new pharmacological strategies. Researchers could be able to inhibit the damaging activity of the complex in inflammation and look forward to unexplored opportunities in anti-inflammatory pharmacological research.
Read the full article about the study
Discover more and purchase High Mobility Group Box 1 and CXCL12
